FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160648265> ?p ?o ?g. }

• W2160648265 endingPage "102" @default.
• W2160648265 startingPage "95" @default.
• W2160648265 abstract "Conversion of the biophysically active large surfactant aggregate subtype (LA) of alveolar surfactant into the less surface active small surfactant aggregates (SA) occurs in vivo and is reproduced under conditions of cyclic surface area changes in vitro. A serine-active carboxyl esterase has been suggested as the responsible enzymatic activity, although the exact mechanisms underlying the conversion process are presently unclear. We investigated the influence of exogenous serine proteases and synthetic and natural serine protease inhibitors on the conversion kinetics of natural rabbit surfactant, obtained as bronchoalveolar lavage fluid (BALF). In vitro cycling of BALF was performed for various time periods in the absence or presence of increasing amounts of several serine proteases (trypsin, plasmin, thrombin, tryptase), and one natural (aprotinin) and 25 synthetic serine protease inhibitors (including regular benzamidines [group A], 3-amidinophenylalanine derivatives [group B], bis-benzamidines [group C], and analogs of naphthylsulfonyl-glycyl-4-amidinophenylalanine piperidide [group D]). LA were separated from SA by 48,000 x g centrifugation. Surface activity of the LA fraction was measured by means of the pulsating bubble surfactometer. None of the classical serine proteases forwarded any acceleration of the LA-to-SA conversion kinetics. Some of the serine protease inhibitors caused moderate retardation of conversion, but at the same dose range inhibited the surface tension-lowering properties of the LA fraction, which per se explained their inhibitory effect. In contrast, specific dose-dependent inhibition of the LA-to-SA transition was observed for four derivatives of the bis-benzamidine group: full blockage of conversion over 240 min of cycling was noted at doses that did not interfere with the surface activity of the LA fraction. In addition, the prototype of these bis-benzamidines, 1,4-bis-[beta-naphthylsulfonyl-(3-aminophenylalanine)]-piperazide, was found to inhibit the activity of the rabbit liver carboxylesterase ES-2 in two different synthetic substrate assays reflecting the amidase and esterase properties of carboxylesterases. These findings support the hypothesis that the LA-to-SA conversion is an enzymatically-driven process with serine-active carboxyl esterase(s) being centrally involved. Synthetic bis-benzamidine-type serine protease inhibitors may offer specific inhibition of this event." @default.
• W2160648265 created "2016-06-24" @default.
• W2160648265 creator A5016511599 @default.
• W2160648265 creator A5028451549 @default.
• W2160648265 creator A5043026704 @default.
• W2160648265 creator A5051814444 @default.
• W2160648265 creator A5069108662 @default.
• W2160648265 creator A5084935661 @default.
• W2160648265 creator A5086392821 @default.
• W2160648265 creator A5086416072 @default.
• W2160648265 date "2003-01-01" @default.
• W2160648265 modified "2023-09-26" @default.
• W2160648265 title "Selective Inhibition of Large-to-Small Surfactant Aggregate Conversion by Serine Protease Inhibitors of the bis-Benzamidine Type" @default.
• W2160648265 cites W1868251026 @default.
• W2160648265 cites W1879361980 @default.
• W2160648265 cites W1945686552 @default.
• W2160648265 cites W1948312511 @default.
• W2160648265 cites W1964459092 @default.
• W2160648265 cites W1965742063 @default.
• W2160648265 cites W1967128898 @default.
• W2160648265 cites W2003709444 @default.
• W2160648265 cites W2013859662 @default.
• W2160648265 cites W2046634819 @default.
• W2160648265 cites W2049617601 @default.
• W2160648265 cites W2066304714 @default.
• W2160648265 cites W2071184125 @default.
• W2160648265 cites W2095566230 @default.
• W2160648265 cites W2144964209 @default.
• W2160648265 cites W2152311269 @default.
• W2160648265 cites W2166443939 @default.
• W2160648265 cites W2268142084 @default.
• W2160648265 cites W2289744294 @default.
• W2160648265 cites W2321826222 @default.
• W2160648265 cites W2338425394 @default.
• W2160648265 cites W2339647566 @default.
• W2160648265 cites W2410160153 @default.
• W2160648265 doi "https://doi.org/10.1165/rcmb.4591" @default.
• W2160648265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12495937" @default.
• W2160648265 hasPublicationYear "2003" @default.
• W2160648265 type Work @default.
• W2160648265 sameAs 2160648265 @default.
• W2160648265 citedByCount "9" @default.
• W2160648265 countsByYear W21606482652018 @default.
• W2160648265 countsByYear W21606482652019 @default.
• W2160648265 countsByYear W21606482652020 @default.
• W2160648265 crossrefType "journal-article" @default.
• W2160648265 hasAuthorship W2160648265A5016511599 @default.
• W2160648265 hasAuthorship W2160648265A5028451549 @default.
• W2160648265 hasAuthorship W2160648265A5043026704 @default.
• W2160648265 hasAuthorship W2160648265A5051814444 @default.
• W2160648265 hasAuthorship W2160648265A5069108662 @default.
• W2160648265 hasAuthorship W2160648265A5084935661 @default.
• W2160648265 hasAuthorship W2160648265A5086392821 @default.
• W2160648265 hasAuthorship W2160648265A5086416072 @default.
• W2160648265 hasConcept C181199279 @default.
• W2160648265 hasConcept C182220744 @default.
• W2160648265 hasConcept C185592680 @default.
• W2160648265 hasConcept C203014093 @default.
• W2160648265 hasConcept C2776414213 @default.
• W2160648265 hasConcept C2776714187 @default.
• W2160648265 hasConcept C2777292125 @default.
• W2160648265 hasConcept C2777807008 @default.
• W2160648265 hasConcept C2779288520 @default.
• W2160648265 hasConcept C2780340462 @default.
• W2160648265 hasConcept C2781071845 @default.
• W2160648265 hasConcept C2909000736 @default.
• W2160648265 hasConcept C43617362 @default.
• W2160648265 hasConcept C52853521 @default.
• W2160648265 hasConcept C55493867 @default.
• W2160648265 hasConcept C58226133 @default.
• W2160648265 hasConcept C86803240 @default.
• W2160648265 hasConcept C89560881 @default.
• W2160648265 hasConceptScore W2160648265C181199279 @default.
• W2160648265 hasConceptScore W2160648265C182220744 @default.
• W2160648265 hasConceptScore W2160648265C185592680 @default.
• W2160648265 hasConceptScore W2160648265C203014093 @default.
• W2160648265 hasConceptScore W2160648265C2776414213 @default.
• W2160648265 hasConceptScore W2160648265C2776714187 @default.
• W2160648265 hasConceptScore W2160648265C2777292125 @default.
• W2160648265 hasConceptScore W2160648265C2777807008 @default.
• W2160648265 hasConceptScore W2160648265C2779288520 @default.
• W2160648265 hasConceptScore W2160648265C2780340462 @default.
• W2160648265 hasConceptScore W2160648265C2781071845 @default.
• W2160648265 hasConceptScore W2160648265C2909000736 @default.
• W2160648265 hasConceptScore W2160648265C43617362 @default.
• W2160648265 hasConceptScore W2160648265C52853521 @default.
• W2160648265 hasConceptScore W2160648265C55493867 @default.
• W2160648265 hasConceptScore W2160648265C58226133 @default.
• W2160648265 hasConceptScore W2160648265C86803240 @default.
• W2160648265 hasConceptScore W2160648265C89560881 @default.
• W2160648265 hasIssue "1" @default.
• W2160648265 hasLocation W21606482651 @default.
• W2160648265 hasLocation W21606482652 @default.
• W2160648265 hasOpenAccess W2160648265 @default.
• W2160648265 hasPrimaryLocation W21606482651 @default.
• W2160648265 hasRelatedWork W2003827752 @default.
• W2160648265 hasRelatedWork W2011302121 @default.
• W2160648265 hasRelatedWork W2041017038 @default.

• next